- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07808112
CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation (ABRAXAS)
Phase II Open-Label, Randomized-Controlled Trial of CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
Contatti e Sedi
Contatto studio
- Nome: Medical College of Wisconsin Cancer Center Clinical Trials Office
- Numero di telefono: 8900 866-680-0505
- Email: cccto@mcw.edu
Luoghi di studio
-
-
Wisconsin
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Froedtert & the Medical College of Wisconsin
-
Contatto:
- Sameem Abedin, MD
- Numero di telefono: 414-805-4600
- Email: sabedin@mcw.edu
-
Investigatore principale:
- Sameem Abedin, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Age ≥18 years.
Patients with a history of a hematologic malignancy with a planned myeloablative conditioning (MAC) peripheral blood allogeneic HCT.
a. Note: Patients with acute leukemia must be in morphologic complete remission with or without hematologic recovery with ≤5% blasts in the bone marrow. Patients with Chronic Myelomonocytic Leukemia (CMML) must have a white blood cell (WBC) count ≤10,000 cells/µL and ≤5% blasts in the marrow. Patients with ≥5% blasts due to a regenerating marrow must contact the protocol chairs for review. Patients with a diagnosis of myelofibrosis require sponsor approval before enrolling.
- Patients must be receiving an allograft from a suitable HLA-matched sibling or (7/8 or 8/8) unrelated donor according to transplant center's guidelines (for selection of appropriate donor).
The following laboratory values obtained ≤14 days prior to registration/randomization:
- Total bilirubin ≤1.5 x ULN or total bilirubin ≤3.0 x the Upper Limit of Normal (ULN) in the presence of Gilbert's syndrome. If total bilirubin is abnormal (≥1.5 x ULN), assess direct bilirubin. NOTE: Patients with Gilbert Syndrome and elevated baseline unconjugated (indirect) bilirubin up to 3.0 mg/dL are eligible. Gilbert syndrome should be confirmed by the presence of UGT1A1*28 variant.
- Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤2.5 x ULN).
- Calculated creatinine clearance ≥30 mL/min using the Cockcroft-Gault formula below:
Creatinine clearance for males = (140 - age)(weight in kg) /(72)(serum creatinine in mg⁄dL) Creatinine clearance for females = (140 - age)(weight in kg) (0.85) /(72)(serum creatinine in mg⁄dL)
- Negative serum pregnancy test done ≤7 days prior to registration/randomization, for persons of childbearing potential only.
Sexually active patients and their partners must use an effective method of contraception associated with a low failure rate prior to study entry and for the duration of study participation and for at least 3 months after the last dose of study drug.
a. Note: The following are considered effective contraceptives: oral contraceptive pill; condom plus spermicide; diaphragm plus spermicide; patient or partner surgically sterile; patient or partner more than 12 months postmenopausal; or injectable or implantable agent/device. Male patients should refrain from sperm donation and female patients should refrain from breastfeeding throughout this period.
- Ability to understand and provide written informed consent at the time of initial study enrollment. Participants who later lose decisional capacity may remain on study with consent from a legally authorized representative (LAR), as applicable.
- Willingness to provide mandatory blood and bone marrow aspirate specimens for correlative research.
- Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study).
Exclusion Criteria:
Any of the following because this study involves an investigational agent whose genotoxic, mutagenic, and teratogenic effect on the developing fetus and newborn are unknown:
- Pregnant persons.
- Nursing persons.
- Persons of childbearing potential, and persons able to father a child, who are unwilling to employ adequate contraception.
Any of the following current or prior therapies:
- Patients receiving a cord blood transplant.
- Patients undergoing a T-cell depleted allogeneic transplantation (using ex vivo CD34 selection, or with serotherapy [antithymocyte globulin or alemtuzumab]).
- Patients undergoing a second allogeneic transplant (after a previous allogeneic transplant).
- Pre-planned treatment with JAK1/JAK2 inhibitor after transplant.
- Previous exposure to axatilimab.
- Receiving an investigational treatment ≤28 days prior to registration/randomization.
- Major surgery ≤3 weeks prior to registration/randomization.
- Chemotherapy ≤2 weeks prior to registration/randomization unless chemotherapy is part of the pre-transplant conditioning.
- Radiation therapy ≤2 weeks prior to registration/randomization unless radiation is part of the pre-transplant conditioning.
- Planned use of Donor Lymphocyte Infusion (DLI) therapy.
- Exception: Use of maintenance regimens as routine clinical care will be permitted but must be declared prior to registration/randomization. The trial does not restrict subsequent treatment after meeting the GFS endpoint.
- Active central nervous system (CNS) involvement by malignant cells.
- Leukemia involvement in the CNS ≤4 weeks of registration for patients with a history of prior CNS leukemia involvement (i.e., leukemic blasts previously detected in the cerebral spinal fluid).
- History of acute or chronic pancreatitis.
- History of myositis.
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
Patients with active hepatitis B or C.
a. Patients with a history of hepatitis B or C are allowed if HBV DNA or HCV RNA are undetectable.
- Any known infection with human immunodeficiency virus (HIV), HTLV-1.
- Uncontrolled bacterial, viral, or fungal infections (currently taking medication and with progression or no clinical improvement) at the time of registration/randomization.
- Psychiatric illness/social situations that would limit compliance with study requirements.
- Diagnosed with another malignancy (other than malignancy for which transplant was performed) ≤ 3 years of registration/randomization, unless previously treated with curative intent and approved by PI (e.g., but not limited to completely resected basal cell, squamous cell, or ductal carcinoma in situ, or low-risk prostate cancer after curative resection or on watchful waiting). In patients with transformed disease (e.g. aggressive lymphoma evolving from CLL, or acute leukemia from MDS), the original hematological disorder is not considered an exclusion. Cancer treated with curative intent <3 years previously will not be allowed unless approved by any of the Study Chairs.
- History of myocardial infarction ≤6 months, or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Safety Run-in
An early safety analysis will be performed after the first 6 evaluable patients have been accrued to Dose Level 1 of the study and observed for four cycles of axatilimab (Cycles 1-4).
Accrual will be temporarily halted while these patients are evaluated.
If 2 or more of the first 6 patients experience a significant toxicity, then the protocol may be amended and the dose of axatilimab may be de-escalated to Dose Level -1.
|
Subjects will receive a first HLA-matched related or (7/8 or 8/8) unrelated donor myeloablative allogeneic HCT.
Cyclophosphamide will be given on Day +3 and Day +4 per institutional practices, at a dose of 50 mg/kg IBW.
Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume), or according to institutional standards.
Altri nomi:
Tacrolimus will be given per institutional practices, starting on Day +5.
Subsequent dosing will be based on blood levels per institutional guidelines with a suggested range of 5-12 ng/mL.
Mycophenolate mofetil (MMF) will be given per institutional practices, at a dose of 15 mg/kg three times daily (TID; based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO).
MMF prophylaxis will start Day +5 and continue until Day +35 post-transplant, at which time it should be discontinued (no taper necessary).
The dose is dependent on the results of the safety run-in.
The starting dose of the safety run-in is 0.3 mg/kg (maximum of 35 mg).
If Dose Level 1 has an unacceptable level of toxicity (≥2 patients having significant toxicity), then axatilimab may be de-escalated to 0.2 mg/kg (maximum of 23 mg).
Altri nomi:
|
|
Sperimentale: Axatilimab Treatment
Starts 35 (±5) days from stem cell transplant; Dosing will occur every 14 days for a maximum of 12 cycles.
|
Subjects will receive a first HLA-matched related or (7/8 or 8/8) unrelated donor myeloablative allogeneic HCT.
Cyclophosphamide will be given on Day +3 and Day +4 per institutional practices, at a dose of 50 mg/kg IBW.
Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume), or according to institutional standards.
Altri nomi:
Tacrolimus will be given per institutional practices, starting on Day +5.
Subsequent dosing will be based on blood levels per institutional guidelines with a suggested range of 5-12 ng/mL.
Mycophenolate mofetil (MMF) will be given per institutional practices, at a dose of 15 mg/kg three times daily (TID; based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO).
MMF prophylaxis will start Day +5 and continue until Day +35 post-transplant, at which time it should be discontinued (no taper necessary).
The dose is dependent on the results of the safety run-in.
The starting dose of the safety run-in is 0.3 mg/kg (maximum of 35 mg).
If Dose Level 1 has an unacceptable level of toxicity (≥2 patients having significant toxicity), then axatilimab may be de-escalated to 0.2 mg/kg (maximum of 23 mg).
Altri nomi:
|
|
Sperimentale: No Axatilimab Treatment
Starts 35 (±5) days from stem cell transplant.
|
Subjects will receive a first HLA-matched related or (7/8 or 8/8) unrelated donor myeloablative allogeneic HCT.
Cyclophosphamide will be given on Day +3 and Day +4 per institutional practices, at a dose of 50 mg/kg IBW.
Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume), or according to institutional standards.
Altri nomi:
Tacrolimus will be given per institutional practices, starting on Day +5.
Subsequent dosing will be based on blood levels per institutional guidelines with a suggested range of 5-12 ng/mL.
Mycophenolate mofetil (MMF) will be given per institutional practices, at a dose of 15 mg/kg three times daily (TID; based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO).
MMF prophylaxis will start Day +5 and continue until Day +35 post-transplant, at which time it should be discontinued (no taper necessary).
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
GVHD-free survival
Lasso di tempo: 1 Year Post HCT
|
A patient will be considered a success for 1-year GVHD-free survival if they are alive without Grade 3 or 4 acute GVHD or systemic immunosuppression requiring chronic GVHD at one year post transplant.
Death, Grade 3 or 4 acute GVHD, and immunosuppression-requiring chronic GVHD (of any severity) prior to 1 year will be considered as events.
|
1 Year Post HCT
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Sameem Abedin, MD, Medical College of Wisconsin
- Cattedra di studio: Mehdi Hamadani, MD, Medical College of Wisconsin
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Malattie del sistema immunitario
- Malattie ematologiche
- Malattie emiche e linfatiche
- Neoplasie ematologiche
- Malattia del trapianto contro l'ospite
- Prodotti chimici organici
- Terapie
- Acidi grassi
- Lipidi
- Procedure chirurgiche, operative
- Idrocarburi
- Acidi, aciclici
- Acidi carbossilici
- Trapianto
- Macrolidi
- Lattoni
- Senape di fosforamide
- Composti di senape di azoto
- Composti di senape
- Idrocarburi, alogenati
- Fosforamidi
- Composti organofosfori
- Trapianto di cellule
- Terapia a base di cellule e tessuti
- Terapia biologica
- Caproati
- Ciclofosfamide
- Acido micofenolico
- Tacrolimo
- Trapianto di cellule staminali
- axatilimab
Altri numeri di identificazione dello studio
- IIT-HAMADANI-ABRAXAS
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .